{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-005189","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.651583+00:00","generated_at":"2026-06-11T19:08:05.191218+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MiNK reports Q2 2023 net loss $6.2M; cash low at $10.6M; Phase 2 gastric trial planned","bullets":["Six-month 2023 net loss $11.9M ($0.35/share) vs $13.9M ($0.41) in prior year period.","Cash $10.6M at June 30, 2023, down from $14.9M at March 31, 2023; Q2 cash used $4.1M.","Externally funded randomized Phase 2 trial in 2L gastric cancer planned at MSKCC; IND for MiNK-215 on track for 2024.","AgenT-797 showed 75% survival in COVID-19 ARDS patients vs 30% in-hospital controls; dosed up to 1B cells."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-005189","json":"https://secwatch.observer/filing/0001171843-23-005189.json","markdown":"https://secwatch.observer/filing/0001171843-23-005189.md","text":"https://secwatch.observer/filing/0001171843-23-005189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323005189/0001171843-23-005189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323005189/f8k_081023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:08:05.191218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc7915a4667836ea3b93fce6ac4c5ed289812f11","claim":"MiNK Therapeutics, Inc. reported the second quarter 2023 results: net income Net loss for the six-months ended June 30, 2023 was $11.9 million, or $0.35 per share.","evidence_excerpt":"On August 10, 2023, MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323005189/0001171843-23-005189-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter 2023"},{"label":"Net income","value":"Net loss for the six-months ended June 30, 2023 was $11.9 million, or $0.35 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}